Release Date: February 27, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q: Alan, regarding the Phase I NCI data with Enhertu, do you expect interim data to be presented at a medical conference like ASCO, or will it be released in a press release? A: Ed, thanks for the question. It has been submitted to either AACR or ASCO. So, I would expect it to be presented at one of those two conferences.
Q: Jeff, can you provide statistics on persistence and compliance for NERLYNX, and what steps are you taking to improve these metrics? A: Yes, Ed. We are educating customers using clinical data showing benefits of staying on therapy for more than 11 months. We work closely with SP partners and sales reps to monitor refills and engage with customers. Our marketing team is also creating materials to support patients throughout their therapy. Data shows about 5% to 10% more patients remain on therapy when starting at a lower dose.
Q: The revenue guidance for the year seems flat. How are you considering price versus volume in that guidance? A: We see a decrease in product supply revenue in 2025 versus 2024. We took a 7% price increase in early Q1 2025. Demand declined about 9% or 10% year over year last year, and we are forecasting a demand decline of about 2% for this year.
Q: Regarding the royalty stream from outside the US, you mentioned China would be down. Should we expect China to be lumpy with revenue boluses and then nothing again in 2025? A: Yes, Ed. China's revenue is lumpy due to its distribution network. We built up inventory ahead of transferring registration authorization to Pierre Fabre, so shipments will be lower in 2025, contributing to the decline in royalties.
Q: On the breast cancer trial for alisertib, what are your expectations for the interim data? A: We will have a better idea of patient numbers in the next earnings call. Patients are randomized to one of three doses, and we expect early response and duration data. The TBCRC 041 trial, with a median PFS of 5.5 months, serves as a benchmark.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。